Rethinking the Role of Second-Line Chemotherapy in Advanced Lung Cancer
At Great Debates Solid Tumors in Miami, Florida, Daniel Rosas, MD, from Memorial Healthcare System, Hollywood, Florida, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.
Dr Rosas argues against the default use of chemotherapy, highlighting emerging therapies such as antibody-drug conjugates and bispecific antibodies that may improve outcomes, and emphasizes the need for future trials incorporating diverse populations and meaningful endpoints such as overall survival and quality of life.
Source:
Rosas D. Treatment after progression on chemoimmunotherapy in lung cancer: Continuing standard cytotoxic therapy vs transitioning to alternative approaches. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
